N-cyclohexylthiophen-2-ylmethylamine | 51305-86-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-cyclohexylthiophen-2-ylmethylamine
• 英文别名: N-(2-thienylmethyl)cyclohexanamine；cyclohexyl-thiophen-2-ylmethyl-amine；N-[(2-thienyl)methyl]cyclohexylamine；2-Cyclohexylaminomethylthiophen；N-(thiophen-2-ylmethyl)cyclohexanamine
• CAS: 51305-86-3
• 化学式: C₁₁H₁₇NS
• mdl: MFCD04491291
• 分子量: 195.329
• InChiKey: IUBVIOLKUAZEJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.636
• 拓扑面积：
  40.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-(Thiophen-2-ylmethyl)cyclohexanamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-(Thiophen-2-ylmethyl)cyclohexanamine
CAS number: 51305-86-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H17NS
Molecular weight: 195.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-cyclohexylthiophen-2-ylmethylamine 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 4-[cyclohexyl(2-thienylmethyl)amino]-6-(4-morpholinyl)-1,3,5-triazine-2-carbonitrile
  参考文献：
  名称：

  优化的三嗪腈作为罗德萨因抑制剂：结构与活性之间的关系，生物等位咪唑并吡啶腈和人组织蛋白酶L的X射线晶体结构分析

  摘要：

  引起非洲昏睡病的布鲁氏锥虫寄生虫的半胱氨酸蛋白酶罗氏蛋白酶已成为开发新候选药物的目标。基于三嗪腈部分作为亲电头基，使用基于结构的设计对酶的S1，S2和S3口袋的取代基进行了优化研究，得到了抑制剂，其抑制常数在个位数纳摩尔范围内。全面的结构-活性关系阐明了活性位点各个口袋的结合偏好。S1口袋可容忍各种取代基，其中优先选择挠性和碱性侧链。S2取代基的变化导致抑制亲和力低至2 n M的高亲和力配体用于带有环己基取代基的化合物。对S3口袋的系统研究表明，它有可能通过芳香族载体实现高活性，这些芳香族载体与形成口袋的一部分的平面肽骨架进行堆叠相互作用。用结构相关酶人组织蛋白酶L的X射线晶体结构分析证实了分子建模所提出的三嗪配体系列的结合模式。通过优化周期确定的最佳取代基修饰的配体可实现亚微摩尔对培养寄生虫增殖的抑制。在基于细胞的测定中，在抑制剂上引入基本侧链导致抗锥虫活性提高了35倍。最后，为了减少三

  DOI：

  10.1002/cmdc.201300112
• 作为产物：
  描述：

  N-环己基-2-噻吩羧酰胺 在 2-氟吡啶 、 三氟甲磺酸酐 、 三乙基硅烷 、 二氢吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以86%的产率得到N-cyclohexylthiophen-2-ylmethylamine
  参考文献：
  名称：

  仲酰胺的受控和化学选择性还原

  摘要：

  该通讯描述了一种不含金属的方法，该方法涉及在环境压力和温度下以良好至极好的收率将仲酰胺有效且受控地还原为亚胺、醛和胺。该方法包括在 2-氟吡啶存在下用三氟甲磺酸酐对仲酰胺进行化学选择性活化。然后可以使用三乙基硅烷（一种廉价、惰性且可商购的试剂）将亲电活化的酰胺还原为相应的亚胺鎓。亚胺可以在碱性处理后分离，也可以在酸性处理后容易地转化为醛。通过在一锅反应中加入硅烷和 Hantzsch 酯氢化物，可以通过顺序还原胺化获得胺部分。而且，

  DOI：

  10.1021/ja105194s

文献信息

• Discovery and development of a novel class of phenoxyacetyl amides as highly potent TRPM8 agonists for use as cooling agents
  作者：Alain Noncovich、Chad Priest、Jane Ung、Andrew P. Patron、Guy Servant、Paul Brust、Nicole Servant、Nathan Faber、Hanghui Liu、Nicole S. Gonsalves、Tanya L. Ditschun

  DOI：10.1016/j.bmcl.2017.04.003

  日期：2017.8

  The paper presents the activity trends for a novel series of phenoxyacetyl amides as human TRPM8 receptor agonists. This series encompasses in vitro activity values ranging from the micromolar to the picomolar levels. Sensory evaluation of these molecules highlights their relevance as cooling agents for oral applications. The positive outcome of the complete evaluation of N-(1H-pyrazol-3-yl)-N-(th

  本文介绍了一系列新型的苯氧基乙酰酰胺作为人类TRPM8受体激动剂的活性趋势。该系列涵盖了从微摩尔到皮摩尔水平的体外活性值。这些分子的感官评估突显了它们作为口腔用清凉剂的重要性。对N-（1H-吡唑-3-基）-N-（噻吩-2-基甲基）-2-（对甲苯氧基）乙酰胺进行全面评估的积极结果导致批准了公认的安全（GRAS）调味品和提取物制造商协会（FEMA）的状态为FEMA 4809。
• [EN] INHIBITORS OF IRAK4 ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ D'IRAK4
  申请人：MERCK SHARP & DOHME

  公开号：WO2016053769A1

  公开（公告）日：2016-04-07

  The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

  本发明涉及式I的IRAK4抑制剂，并提供包含这种抑制剂的组合物，以及用于治疗IRAK4介导或相关疾病或疾病的方法。
• PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS
  申请人：ARIAD PHARMACEUTICALS, INC.

  公开号：EP3210609A1

  公开（公告）日：2017-08-30

  The invention features compounds of the general formula (VIa) in which the variable groups are as defined herein, and to their preparation and use.

  该发明涉及一般式（VIa）的化合物，其中变量基团如本文所定义，以及它们的制备和使用。
• Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same
  申请人：——

  公开号：US20040224959A1

  公开（公告）日：2004-11-11

  Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R 1 and R 2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R 1 and R 2 , together with a nitrogen atom to which R 1 and R 2 are attached, may form a ring; R 3 and R 4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R 2 and R 3 may be attached to each other to form —(CH 2 ) m —, —N═CH—, —CH═N—, or —(C 1-6 alkyl)C═N—; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group —C(═O)N(R 5 )R 6 or group —C(═O)OR 7 , R 8 is absent or represents a bond, an oxygen atom, a sulfur atom, —SO 2 —, —SO—, —CH 2 —CH 2 —, or —CH═CH—, and R 9 and R 10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents —(CH 2 ) n —, —O—(CH 2 ) i —, or —C(═O)NH—(CH 2 ) i —. 1

  本发明涉及一种由公式（I）表示的化合物，其在肝脏中具有三酰甘油生物合成抑制活性和抑制含载脂蛋白B的脂蛋白从肝脏分泌的活性，特别是对含载脂蛋白B的脂蛋白的分泌具有出色的抑制活性，且不会出现在肝脏中积累脂质的副作用，对于治疗和预防高脂血症和动脉粥样硬化疾病非常有用。在公式（I）中，R1和R2代表烷基、烷氧基、环烷基、苯基、烯基、炔基或五元或六元饱和或不饱和杂环环，或R1和R2与R1和R2附着的氮原子一起形成环; R3和R4代表氢原子、烷基、卤素原子、羟基、腈、烷氧羰基、烷氧基或羧基; 或R2和R3可以相互附着以形成-（CH2）m-、-N═CH-、-CH═N-或-（C1-6烷基）C═N-; A、D、E和G每个代表一个碳原子，或任何一个A、D、E和G代表一个氮原子，其他三个代表一个碳原子; Q代表一个氮原子或一个碳原子; Y代表由公式（II）表示的基团，其中X代表氢原子、基团-C(═O)N(R5)R6或基团-C(═O)OR7，R8不存在或代表一个键，一个氧原子，一个硫原子，-SO2-，-SO-，-CH2-CH2-或-CH═CH-，R9和R10代表氢原子、烷基、烷氧基、卤素原子或羟基; Z代表-（CH2）n-、-O-（CH2）i-或-C(═O)NH-（CH2）i-。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1180514A1

  公开（公告）日：2002-02-20

  Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R1 and R2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R1 and R2, together with a nitrogen atom to which R1 and R2 are attached, may form a ring; R3 and R4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R2 and R3 may be attached to each other to form -(CH2)m-, -N=CH-, -CH=N-, or -(C1-6 alkyl)C=N-; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group -C(=O)N(R5)R6 or group -C(=O)OR7, R8 is absent or represents a bond, an oxygen atom, a sulfur atom, -SO2-, -SO-, -CH2-CH2-, or - CH=CH-, and R9 and R10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents - (CH2)n-, -O-(CH2)i-, or -C(=O)NH-(CH2)i-.

  本发明公开了式(I)代表的化合物，该化合物具有抑制肝脏中甘油三酯生物合成的活性和抑制肝脏分泌含脂蛋白B的脂蛋白的活性，特别是对肝脏分泌含脂蛋白B的脂蛋白具有极好的抑制活性，无肝脏中脂类蓄积的副作用，可用于治疗和预防高脂血症和动脉硬化性疾病。在式（I）中，R1 和 R2 代表烷基、烷氧基、环烷基、苯基、烯基、炔基或五元或六元饱和或不饱和杂环，或 R1 和 R2 与 R1 和 R2 所连接的氮原子一起可形成一个环；R3 和 R4 代表氢原子、烷基、卤素原子、羟基、腈基、烷氧羰基、烷氧基或羧基；或 R2 和 R3 可相互连接形成-(CH2)m-、-N=CH-、-CH=N-或-(C1-6 烷基)C=N-；A、D、E 和 G 各代表一个碳原子，或 A、D、E 和 G 中的任何一个代表一个氮原子，其他三个各代表一个碳原子； Q 代表一个氮原子或一个碳原子；Y 代表由式 (II) 所代表的基团，其中 X 代表氢原子、基团-C(=O)N(R5)R6 或基团-C(=O)OR7，R8 不存在或代表键、氧原子、硫原子、-SO2-、-SO-、-CH2-CH2- 或-CH=CH-，R9 和 R10 代表氢原子、烷基、烷氧基、卤素原子或羟基；Z 代表-(CH2)n-、-O-(CH2)-i 或-C(=O)NH-(CH2)-i。